Nitrates for acute heart failure syndromes

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Wakai, Abel ^a   Mccabe, Aileen ^a   Kidney, Rachel ^b   Brooks, Steven C ^c   Seupaul, Rawle A ^d   Diercks, Deborah B ^e   Salter, Nigel ^f   Fermann, Gregory J ^g   Pospisil, Caroline ^h  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; MORPHINE; NESIRITIDE; NITRIC ACID DERIVATIVE; PRENALTEROL; NITRATE; VASODILATOR AGENT;

ABDOMINAL PAIN; ACUTE HEART FAILURE; CARDIOVASCULAR RESPONSE; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEALTH CARE COST; HEART RATE; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; ADULT; HEART FAILURE; META ANALYSIS; SYNDROME;

ACUTE DISEASE; ADULT; HEART FAILURE; HUMANS; ISOSORBIDE DINITRATE; NITRATES; NITROGLYCERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME; VASODILATOR AGENTS;

EID: 84893043943     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005151.pub2     Document Type: Review

References (68)

1. Beltrame J, Zeitz C, Unger S, Brennan R, Moran J, Horowitz J. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary oedema. Journal of Cardiac Failure 1998;4(4):271-9. [PUBMED: 9924848]
2. Nelson GIC, Silke B, Ahuja RC, Hussain M, Taylor SH. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart failure following myocardial infarction. Lancet 1983;321:730-3. [PUBMED: 6132082]
3. Verma SP, Silke B, Hussain M, Nelson G, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. Journal of Cardiovascular Pharmacology 1987;10:38-46. [PUBMED: 2441152]
4. Publication committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002;287(12):1531-40. [PUBMED: 11911755]
5. Cotter G, Metzkor E, Kaluski E, Faigenberg Z. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93. [PUBMED: 9482291]
6. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. American Journal of Cardiology 2004;93:237-40. [PUBMED: 14715359]
7. Adamson PB, Zile MR, Cho YK, Bennett TD, Bourge RC, Aaron MF, et al. Hemodynamic factors associated with acute decompensated heart failure: part 2-use in automated detection. Journal of Cardiac Failure 2011;17(5):366-73. [PUBMED: 21549292]
8. The ADHERE Registry. First Quarter 2003 National Benchmark Report. The ADHERE Registry 2003.
9. Heart and stroke statistical update. American Heart Association 2001.
10. Ambrosioni E, Borghi C, Magnani B (The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators). The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after myocardial infarction. New England Journal of Medicine 1995;332:80-5.
11. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. European Journal of Heart Failure 2001;3:283-91.
12. Bueno H, Vidan MT, Almazan A, Lopez-Sendon JL, Delcan JL. Influence of sex on the short-term outcome of elderly patients with a first acute myocardial infarction. Circulation 1995;92:1133-40.
13. Campana C, Gavazii A, Berzuini C, Larizza C, Marioni R, D'Armini A, et al. Predictors of prognosis in patients awaiting heart transplantation. Journal of Heart and Lung Transplantation 1993;12:756-65.
14. Cleland JGF, Khand A, Clark A. The heart failure epidemic: exactly how big is it?. European Heart Journal 2001;22:623-6.
15. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme - a survey of the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. European Heart Journal 2003;24:442-63.
16. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000;101:1358-61.
17. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. European Journal of Heart Failure 2003;5:443-51.
18. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Suresh V, et al. The epidemiology of heart failure. European Heart Journal 1997;18:208-25.
19. Crane SD. Epidemiology, treatment and outcome of acidotic, acute, cardiogenic pulmonary oedema presenting to an emergency department. European Journal of Emergency Medicine 2002;9:320-4.
20. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
21. DiDomenico RJ, Park HY, Southworth MR, Eyrich HM, Lewis RK, Finley JM, et al. Guidelines for acute decompensated heart failure treatment. Annals of Pharmacotherapy 2004;38:646-60.
22. DiGuili F, Anand I. Current issues in heart failure. Acute Heart Failure 2001.
23. Doughty R, Yee T, Sharpe N, MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1981-1991. New Zealand Medical Journal 1995;108:473-5.
24. Eriksson H, Wilhelmsen L, Caidahl K, Svardsudd K. Epidemiology and prognosis of heart failure. Zeitschrift fur Kardiologie 1991;80:1-6.
25. Fonarow GC. The treatment targets in acute decompensated heart failure. Reviews in Cardiovascular Medicine 2001;2:S7-S12.
26. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Reviews in Cardiovascular Medicine 2002;3:S18-S27.
27. Fonarow GC (ADHERE Scientific Advisory Committee). The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Reviews in Cardiovascular Medicine 2003;4:S21-S30.
28. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Archives of Internal Medicine 2008;168:847-54. [PUBMED: 18443260]
29. Ghali JK, Cooper R, Ford E. Trends in hospitalisation rates for heart failure in the United States 1973-1986: evidence for screening population prevalence. Archives of Internal Medicine 1992;150:769-73.
30. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;20(112(25)):3958-68.
31. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-23.
32. Glasziou P, Irwig L, Bain C, Colditz G. Systematic Reviews in Health Care: a Practical Guide. Cambridge: Cambridge University Press, 2001.
33. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction: a review. American Journal of Medicine 2002;113:324-30.
34. Higgins JPT, Thompson SG, Deeks JD, Altman G. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60. [MEDLINE: 12958120]
35. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine 1999;341:625-34.
37. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Journal of the American College of Cardiology 2001;38:2101-13.
38. Imhof PR, Ott B, Frankhauser P, Chu LC, Hodler J. Difference in nitroglycerin dose response in the venous and arterial beds. European Journal of Clinical Pharmacology 1980;18:455-60.
39. Anonymous. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
40. Kaluski E, Kobrin I, Zimlichman R, Marmov A, Krakov O, Milo O, et al. RITZ-5: Randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. A prospective, multicenter, double-blind, placebo-controlled study. Journal of the American College of Cardiology 2003;41:204-10.
41. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156:661-6. [PUBMED: 8629879]
42. Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving?. European Journal of Heart Failure 1999;1:229-41.
43. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. In: Mulrow C, Cook D editor(s). Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions. 1st Edition. Philadelphia: American College of Physicians, 1998:91-101.
44. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. Using the Cochrane sensitivity-maximising RCT filter. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. American Heart Journal 2000;140:840-7.
46. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2012;14(8):803-69. [PUBMED: 22828712]
47. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT- dyspnoea study. European Heart Journal 2010;31(7):832-41. [PUBMED: 19906690]
48. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-40.
49. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. European Heart Journal 2008;29(6):816-24. [PUBMED: 18310669]
50. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. European Heart Journal 2010;31(7):784-93. [PUBMED: 20207624]
51. Peacock WF, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. Journal of Cardiac Failure 2004;10:120-5.
52. Reitsma JB, Mosterd A, de Craen AJ, Koster RW, van Capelle FJ, Grobbee DE, et al. Increase in hospital admission rates for heart failure in the Netherlands, 1980-1993. Heart 1996;76:388-92.
53. The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2012.
54. Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. European Heart Journal 1997;18:388-92.
55. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011;1(123(4)):e18-e209.
56. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. National Health Statistics Reports 2008;6(8):1-29.
57. Sharon A, Shpirer I, Kalunski E, Moshkovitz Y, Milovanov O, Polak R, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. Journal of the American College of Cardiology 2000;36:832-7.
58. Spencer FA, Meyer TE, Goldberg RJ, Yarzebski J, Hatton M, Lessard D, et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. Journal of the American College of Cardiology 1999;34:1378-87.
59. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002;105:2605-10. [MEDLINE: 12045165]
60. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004;109:494-9.
61. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. European Journal of Heart Failure 1999;1:251-7.
62. Stewart S, MacIntyre K, Hole DJ. More 'malignant' than cancer? 5-year survival following a first admission with heart failure. European Journal of Heart Failure 2001;3:315-22.
63. Stewart S, Jenkins A, Buchan A, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure 2001;3:361-71.
64. Stewart S, MacIntyre K, Capewell S, McMurray JJV. Heart failure and the aging population: an increasing burden in the 21st century?. Heart 2003;89(1):49-53.
65. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, et al. Acute heart failure syndromes: emergency department presentation, treatment and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010;122(19):1975-96.
66. Whellan DJ, Sarkar S, Koehler J, Small RS, Boyle A, Warman EN, et al. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. American Journal of Cardiology 2013;111(1):79-84. [PUBMED: 23040596]
67. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). Journal of the American College of Cardiology 2002;40:1389-94.
68. Zile MR, Adamson PB, Cho YK, Bennett TD, Bourge RC, Aaron MF, et al. Hemodynamic factors associated with acute decompensated heart failure: part 1-insights into pathophysiology. Journal of Cardiac Failure 2011;17(4):282-91. [PUBMED: 21440865]